688073 Bide Pharmatech
- 33.43
- +1.10+3.40%
Bide Pharmatech News
Open Source Securities released a research report on April 26 stating that it gave Bide Pharmaceutical (688073.SH) a purchase rating. The main reasons for the rating include: 1) accelerating the global layout and continuing high growth in overseas busines
Open Source Securities released a research report on April 26 stating that it gave Bide Pharmaceutical (688073.SH) a purchase rating. The main reasons for the rating include: 1) accelerating the global layout and continuing high growth in overseas business; 2) molecular block SKU, which serves a steady growth in the number of customers. (Mainichi Keizai Shimbun)
Bide Pharmaceutical (688073) Company Information Update Report: Steady growth in operating revenue awaits profit release in 2024
Revenue grew steadily, and short-term profits were pressured by falling gross margin. The company achieved operating income of 1,092 billion yuan in 2023, an increase of 30.94% over the previous year; achieved net profit of 110 million yuan, a year-on-year decrease of 24.94%; achieved
Bide Pharmaceutical (688073.SH) announced its 2023 annual results, net profit of 110 million yuan decreased by 24.94% year-on-year
Bide Pharmaceutical (688073.SH) released its 2023 annual performance report. The company achieved operating income of 1 during the reporting period...
Bide Pharmaceutical (688073.SH): Currently, the cooperation with Huawei is still small
On April 17, Ge Longhui Pharmaceutical (688073.SH) said on the investor interactive platform that Bide Pharmaceutical's main business is to provide customers with products or services related to “molecular blocks and scientific research reagents”. Currently, the company's cooperation with Huawei is still small. If the amount of subsequent orders meet the disclosure standards, it will fulfill its obligation to disclose information. The field of new materials has very good potential for development, and the company has always kept a close eye on it.
Express News | Yesterday, a total of 21 A-share listed companies issued announcements related to share repurchases. Weiyuan Co., Ltd. plans to repurchase no more than 120 million yuan
Bide Pharmaceutical (688073.SH): A total of 2.0675% of the company's shares have been repurchased
Gelonghui, April 10 | Bide Pharmaceutical (688073.SH) announced that as of April 9, 2024, the company had repurchased a total of 1.889,000 shares of the company's shares through the Shanghai Stock Exchange trading system, accounting for 2.0675% of the company's total share capital of 90,882,948 shares, an increase of 0.2893% compared with the previous disclosure. The highest price of the repurchase transaction was 52.99 yuan/share. The lowest price was 32.36 yuan/share, and the total transaction amount was 794.819 million yuan (excluding transaction fees).
Bide Pharmaceutical (688073.SH): Did not buy back the company's shares in March
Gelonghui, April 1 | Bide Pharmaceutical (688073.SH) announced that in March 2024, the company did not buy back the company's shares through centralized bidding transactions through the Shanghai Stock Exchange trading system. As of March 31, 2024, the company has repurchased a total of 1,616,155 shares through the Shanghai Stock Exchange trading system, accounting for 1.7783% of the company's total share capital of 90,882,948 shares. The highest price of the repurchase transaction was 52.99 yuan/share, the lowest price was 32.36 yuan/share, and the total transaction amount was 70,431,395
Are Bide Pharmatech Co., Ltd.'s (SHSE:688073) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
Bide Pharmatech (SHSE:688073) has had a rough three months with its share price down 26%. However, stock prices are usually driven by a company's financials over the long term, which in this case lo
Express News | A-share review: the three major indices collectively adjusted the turnover of the two markets exceeded trillion dollars for five consecutive trading days
Bide Pharmaceutical (688073.SH): Dai Lan increased its holdings by 35,000 shares
Gelonghui, March 20, 丨 Bide Pharmaceutical (688073.SH) announced that from January 24, 2024 to March 19, 2024, Ms. Dai Lan has accumulated 35,000 shares of the company's shares through centralized bidding through the Shanghai Stock Exchange trading system, accounting for 0.0385% of the company's total share capital. The total increase amount is RMB 1.407 million (excluding transaction fees), which has exceeded 50% of the minimum amount of RMB 2.5 million of the current increase plan. Entities that increase their holdings will continue to increase their public holdings during the implementation period of the plans to increase their holdings in accordance with the relevant plans to increase their holdings
Bide Pharmaceutical (688073.SH): The company has not used AI technology
Gelonghui, March 20 | Bide Pharmaceutical (688073.SH) said on the investor interactive platform that at present, the company has not used AI technology. At the same time, the company has been keeping an eye on the progress of AI technology in the field of new drug development.
5.162,200 restricted shares of Bide Pharmaceutical (688073.SH) will be listed and circulated on March 25
Bide Pharmaceutical (688073.SH) announced that the restricted shares currently in circulation are part of the company's initial public offering...
Bide Pharmaceutical (688073.SH): It has spent 704.314 million yuan to buy back a total of 1.7783% of the company's shares
Gelonghui, March 4, 丨 Bide Pharmaceutical (688073.SH) announced that as of February 29, 2024, the company had repurchased a total of 1.616,200 shares of the company's shares through the Shanghai Stock Exchange trading system, accounting for 1.7783% of the company's total share capital of 90,882,948 shares. The highest price of the repurchase transaction was 52.99 yuan/share, the lowest price was 32.36 yuan/share, and the total transaction amount was 704.314 million yuan (excluding transaction fees).
Bide Pharmaceutical (688073.SH): As of February 2, it has repurchased a total of 1.043,800 shares
Gelonghui, Feb. 5 | Bide Pharmaceutical (688073.SH) announced that as of February 2, 2024, the company had repurchased 1,044,800 shares of the company's shares through centralized bidding transactions, accounting for 1.1485% of the company's total share capital of 90,882,948 shares, an increase of 0.3466% compared with the previous disclosure. The highest price of the repurchase transaction was 52.99 yuan/share. The lowest price was 36.93 yuan/share, and the total transaction amount was 496.342 million yuan (excluding transaction fees).
Bide Pharmaceutical (688073.SH): As of January 31, it has repurchased a total of 728,800 shares
Gelonghui, Feb. 2 | Bide Pharmaceutical (688073.SH) announced that as of January 31, 2024, the company had repurchased a total of 728,782 shares through the Shanghai Stock Exchange trading system, accounting for 0.8019% of the company's total share capital of 90,882,948 shares. The highest price of the repurchase transaction was 52.99 yuan/share, the lowest price was 45.81 yuan/share, and the total transaction amount was 37,150,866.62 yuan (excluding transaction fees).
The Recent Pullback Must Have Dismayed Bide Pharmatech Co., Ltd. (SHSE:688073) Insiders Who Own 47% of the Company
Key Insights Bide Pharmatech's significant insider ownership suggests inherent interests in company's expansion 53% of the business is held by the top 3 shareholders Institutional ownership in Bi
Express News | Bide Pharmaceutical: The actual controller plans to increase its holdings by 2.5 million yuan to 5 million yuan
Bide Pharmaceutical (688073.SH): Chairman and General Manager Dai Lan plans to increase the company's shares by 2.5 million yuan to 5 million yuan
On January 23, Ge Longhui Pharmaceutical (688073.SH) announced that based on her confidence in the company's future development and recognition of long-term investment value, Ms. Dai Lan, plans to use her own capital or self-raised capital to increase her holdings of the company through methods permitted by the Shanghai Stock Exchange system (including but not limited to centralized bidding and bulk transactions) within 6 months from January 24, 2024, with an increase of no less than RMB 2.5 million (inclusive) and no more than RMB 5 million (inclusive).
Bide Pharmaceutical (688073.SH): initial repurchase of 90,000 shares
Gelonghui, January 5 | Bide Pharmaceutical (688073.SH) announced that on January 5, 2024, the company repurchased 90,000 shares of the company's shares for the first time through centralized bidding transactions, accounting for 0.0990% of the company's total share capital of 90,882,948 shares. The highest price of the repurchase transaction was 52.09 yuan/share, the lowest price was 51.81 yuan/share, and the total amount of capital paid was RMB 4,673,226.50.
Bide Pharmaceuticals (688073.SH): Repurchase has not been implemented
Gelonghui January 3 | Bide Pharmaceutical (688073.SH) announced that as of December 31, 2023, the company had not implemented a repurchase.
Analysis
Price Target
No Data
